The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 11, 2007
Filed:
Sep. 27, 2004
Richard T. Timmer, Decatur, GA (US);
Christopher W. Alexander, Norcross, GA (US);
Sivaram Pillarisetti, Norcross, GA (US);
Uday Saxena, Atlanta, GA (US);
Koteswar Rao Yeleswarapu, Hyderabad, IN;
Manojit Pal, Hyderabad, IN;
Jangalgar Tirupathy Reddy, Hyderabad, IN;
Velagala Venkata Rama Murali Krishna Reddy, Hyderabad, IN;
Sesha Sridevi Alluri, Hyderabad, IN;
Potlapally Rajender Kumar, Hyderabad, IN;
Gaddam OM Reddy, Hyderabad, IN;
Richard T. Timmer, Decatur, GA (US);
Christopher W. Alexander, Norcross, GA (US);
Sivaram Pillarisetti, Norcross, GA (US);
Uday Saxena, Atlanta, GA (US);
Koteswar Rao Yeleswarapu, Hyderabad, IN;
Manojit Pal, Hyderabad, IN;
Jangalgar Tirupathy Reddy, Hyderabad, IN;
Velagala Venkata Rama Murali Krishna Reddy, Hyderabad, IN;
Sesha Sridevi Alluri, Hyderabad, IN;
Potlapally Rajender Kumar, Hyderabad, IN;
Gaddam Om Reddy, Hyderabad, IN;
Reddy US Therapeutics, Inc., Norcross, GA (US);
Abstract
The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.